Billings Clinic
Especially For:

Clinical Trials

Title   GOG 0241 Ovarian/Fallopian Tube/Primary Peritoneal Cancer: MUCINOUS EPITHELIAL OVARIAN OR FALLOPIAN TUBE CANCER
Description   GOG-0241 A GCIG INTERGROUP MULTICENTER PHASE III TRIAL OF OPEN LABEL CARBOPLATIN & PACLITAXEL +/- NCI-SUPPLIED AGENT: BEVACIZUMAB COMPARED w OXALIPLATIN & CAPECITABINE +/- BEVACIZUMAB AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH MUCINOUS EPITHELIAL OVARIAN OR FALLOPIAN TUBE CANCER (MEOC)
IRB Number   GOG 0241
Category   Gynencology
Inclusion/Notes   Patients may have measurable disease as defined by RECIST 1.1 or no measurable
disease.
3.12 All patients must have had appropriate surgery including appendectomy (unless
patient has history of prior appendectomy) for ovarian or fallopian tube
carcinoma with appropriate tissue available for histologic evaluation to confirm
diagnosis and stage.
3.13 Patients must have stage II-IV disease (no brain metastasis) or recurrent Stage I
disease (chemonaïve).
Status   Active
Start Date   12/14/2010
Principal Investigator (PI)   Randall Gibb, MD
Contact Name   Judy Miller
Contact Email   jmiller4@billingsclinic.org
Phone   (406) 435-7482
Funding Source   NCI
Print This Page
Email to a Friend
Home | Contact | Site Map | Site Privacy Policy | Terms & Conditions | Patient Privacy Policy | Medical Records | Fast Command
2800 10th Ave. North | P.O. Box 37000 | Billings, Montana 59107 | 406.238.2500
© Copyright 2014 Billings Clinic. All Rights Reserved.